LogiCare3PL, a division of BioCare Inc., has secured an exclusive third-party logistics partnership with ChiRhoClin Inc., a Maryland-based pharmaceutical company specializing in pancreatic and gastrointestinal diagnostics. The partnership, effective July 14, 2025, positions LogiCare3PL as the sole distribution provider for ChiRhoStim® (Human Secretin for Injection), ChiRhoClin's flagship diagnostic product.
Strategic Partnership for Orphan Drug Distribution
The collaboration leverages LogiCare3PL's specialized expertise in orphan drug logistics to support ChiRhoClin's mission of providing timely, reliable access to critical diagnostic treatments. As a nationally accredited third-party logistics provider, LogiCare3PL brings deep experience in handling sensitive pharmaceutical products for rare disease applications.
"We're proud to support ChiRhoClin in distributing ChiRhoStim®, a diagnostic product that plays a vital role in patient care," said Kevin Kissling, Vice President & General Manager of LogiCare3PL. "Our team appreciates the importance of reliability and precision in handling sensitive therapies like ChiRhoStim®, and we are committed to delivering a seamless and dependable experience for ChiRhoClin's customers."
Distribution Infrastructure and Capabilities
LogiCare3PL operates two secure, fully accredited distribution centers strategically located in Tempe, Arizona, and Olive Branch, Mississippi. Both facilities are purpose-built for precision and reliability in pharmaceutical logistics, maintaining cGMP compliance and holding accreditation from the National Association of Boards of Pharmacy® (NABP®). The distribution network is equipped to support both domestic and international distribution requirements for high-value, small-batch pharmaceutical products.
Clinical Significance of ChiRhoStim
ChiRhoStim® represents a critical diagnostic tool for pancreatic and gastrointestinal conditions, addressing the needs of patients with rare diseases. ChiRhoClin Inc. focuses on developing orphan drug products specifically for pancreatic and gastrointestinal diseases, with a commitment to advancing diagnostic and therapeutic options for underserved patient populations.
"The LogiCare3PL team has been a proactive and engaged partner as we prepared to distribute ChiRhoStim® through the company's distribution network," said Skip Purich, CEO of ChiRhoClin Inc. "Their experience in orphan drug logistics has been critical to establishing a strong foundation for this launch, and we're confident this partnership will deliver a high level of service to our customers."
Market Impact and Patient Access
The partnership underscores both organizations' commitment to high-touch service and patient-centered care in the orphan drug space. By combining ChiRhoClin's specialized diagnostic product portfolio with LogiCare3PL's distribution expertise, the collaboration aims to enhance access to critical diagnostic treatments for healthcare providers and patients dealing with rare pancreatic and gastrointestinal conditions.
ChiRhoClin also supports ongoing research in the field through its Small Pancreatic Grant Program, demonstrating the company's broader commitment to advancing care for patients with rare conditions beyond product distribution.
